Scientific Presentations
2020
Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
Late Breaking News Session: European Academy of Dermatology and Venereology Virtual Congress
October 29, 2020
New CTP-543 (Oral JAK 1/2 Inhibitor) Phase 2 Analyses: SALT 20 was Statistically Significant From Placebo for the 8 and 12 mg BID Cohorts in Alopecia Areata Trial
Late-Breaking Abstract: American Academy of Dermatology Annual Meeting 2020
June 12, 2020
2019
CTP-543, an Oral JAK Inhibitor, Achieves Primary Endpoint in Phase 2 Randomized, Placebo-Controlled Dose-Ranging Trial in Patients with Moderate-to-Severe Alopecia Areata
28th European Academy of Dermatology and Venereology (EADV) Annual Congress
October 12, 2019
CTP-543, A JAK1/JAK2 Inhibitor, Achieves Primary Endpoint in Interim Analysis of Phase 2 Trial in Alopecia Areata
2019 World Congress for Hair Research Annual Meeting
April 24-27,2019
JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata; An Interim Analysis of 4 and 8 mg BID
American Academy of Dermatology
Late-breaking Research: Clinical Trials
March 2, 2019
2017
Safety and Pharmacokinetic Evaluation of CTP-543 (Deuterated Ruxolitinib) in a Phase 1 Healthy Volunteer Study
2017 American Academy of Dermatology Annual Meeting
March 3-7, 2017
2016
CTP-656 Multiple Dose Pharmacokinetic Profile Continues to Support a Once-Daily Potentiator for Cystic Fibrosis Patients with Gating Mutations
30th Annual North American Cystic Fibrosis Conference
October 27-29, 2016
CTP-656 Tablet Confirmed Superiority of Pharmacokinetic Profile Relative to Kalydeco in Phase 1 Clinical Studies
39th European Cystic Fibrosis Conference
June 8-11, 2016
2015
Pharmacokinetic Studies of Deuterated Isotopologs of Ivacaftor in Preclinical Models and Healthy Volunteers
29th Annual North American Cystic Fibrosis Conference
October 8-10, 2015
